Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Professional Education
- Fellowship: Stanford University Hematology and Oncology Fellowship (2000) CA
- Residency: University of Michigan Health System Internal Medicine Residency (1997) MI
- Internship: University of Michigan Health System Internal Medicine Residency (1995) MI
- Medical Education: University of California at Irvine School of Medicine Registrar (1994) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2003)
Publications
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., … Negrin, R. S. (2000). Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(5), 506–12. -
T cell antigen receptor vaccines for active therapy of T cell malignancies
Reddy, S. A., Okada, C., Wong, C., Bahler, D., & Levy, R. (2001). T cell antigen receptor vaccines for active therapy of T cell malignancies. Presented at the Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma, NEW YORK,NY,NY,NY,NY,NY,NY: NEW YORK ACAD SCIENCES. -
CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., & Kim, Y. H. (2003). CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 49(6), 1049–58. -
Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
Reddy, S. A., & Levy, R. (2004). Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 124(5), 626–28. -
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinkski, D. K., Vojdani, F., … Levy, R. (2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(29), 10131–36. -
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–57. -
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–74. -
A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., … Kim, Y. H. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. CLINICAL CANCER RESEARCH, 15(19), 6217–6224. -
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., … Kim, Y. H. (2010). Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28(29), 4485–91. -
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., … Knox, S. J. (2012). A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. TRANSLATIONAL ONCOLOGY, 5(6), 404–7. -
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. British Journal of Dermatology, 169(3), 673–76. -
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., & Chang, A. L. S. (2013). Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY, 169(3), 673–76. -
Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatology, 150(11), 1209–12. -
Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy. JAMA DERMATOLOGY, 150(11), 1209–12. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., … Whittaker, S. (2015). Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. LEUKEMIA & LYMPHOMA, 56(10), 2847–54. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., & Gephart, M. H. (2016). Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. JOURNAL OF NEURO-ONCOLOGY, 128(1), 93–100. -
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., … Knox, S. J. (2016). A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 96(3), 578–88. -
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., … Cheever, M. A. (2016). PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 374(26), 2542–52. -
Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.
Finlayson, S. G., Levy, M., Reddy, S., & Rubin, D. L. (2016). Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data. Journal of Biomedical Informatics, 60, 104–13. -
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy, S. A. (2016). Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Critical Reviews in Oncology/Hematology, 106, 99–107. -
Phase I Trial: SABR and Ipilimumab-Letter.
Hiniker, S. M., Reddy, S. A., Swetter, S. M., & Knox, S. J. (2017). Phase I Trial: SABR and Ipilimumab-Letter. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(1), 320. -
Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2018). Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology. -
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., … Mittra, E. (2019). Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clinical Nuclear Medicine. -
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., … Topalian, S. L. (2019). Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801896. -
Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., & Knox, S. J. (2018). Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up. Cureus, 10(12), e3723. -
Management of Immunotherapy-Related Toxicities. Version 1.2019
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Scavone, J. L. (2019). Management of Immunotherapy-Related Toxicities. Version 1.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(3), 255–88. -
A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., … Colevas, D. (2019). A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 81(4), AB8. -
Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
Hall, E. T., Zhang, J., Kim, E.-J., Hwang, G., Bhatia, S., & Reddy, S. A. (2019). Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T. M., Conry, R. M., … Ribas, A. (2019). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Hall, E., Zhang, J., Kim, E. J., Hwang, G., Chu, G., Bhatia, S., & Reddy, S. (2020). Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Medicine. -
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., … Engh, A. (2020). NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network : JNCCN, 18(3), 230–41. -
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., … Barker, C. A. (2020). A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., … Franc, B. L. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. -
Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., & Knox, S. J. (2020). Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. Melanoma Management, 7(1), MMT36. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.
Zhang, M., Rodrigues, A. J., Bhambhvani, H. P., Fatemi, P., Pollom, E. L., Gibbs, I. C., … Li, G. (2020). Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma. World Neurosurgery. -
"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma".
Narala, R., Reddy, S. A., & Mruthyunjaya, P. (2020). "Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma". American Journal of Ophthalmology Case Reports, 20, 100891. -
Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS. -
Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., … Franc, B. L. (2021). Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.
Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., … Mahajan, V. B. (2021). Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. Molecular Cancer, 20(1), 39.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma »
- Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors »
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma »
- A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma »
- A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists »
- Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome »
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery »
- Compassionate Use Trial for Unresectable Melanoma With Ipilimumab »
Practice Locations
Cancer Immunotherapy Program Palo Alto, CA
Palo Alto, CA
Cancer Immunotherapy Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Skin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Drive, 3rd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Ocular and Orbital Oncology Palo Alto, CA
Palo Alto, CA
Ocular and Orbital Oncology
2452 Watson Court
Palo Alto , CA 94303
Make An Appointment More Clinic Information » Getting Here »Stanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto Palo Alto, CA
Palo Alto, CA
Stanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto
900 Blake Wilbur Drive, 3rd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(87 reviews)
Dr. Reddy and his PA offered excellent advice concerning following option after my current surgery.
Dr. Reddy and his team are outstanding!
Dr. Reddy listened & heard my concerns.
Excellent.
Dr. Reddy & his N.P. are very knowledgeable & approachable.
Dr. Reddy & his (PA) (NP) are outstanding when visiting with me.
Feel lucky to have Dr. Reddy as my doctor.
Dr. Reddy is wonderful.
I have recommended this facility and this care provider to many persons.
So far my experience at this facility has been enjoyable, friendly and on time.
Knowledgeable, patient.
Excellent doctor & student doctor.
Dr. Reddy is outstanding - both medically and as a human being.
Dr. Reddy is awesome.
Dr. Reddy and his team are wonderful!
I love Stanford and would recommend it to family and friends.
Dr. Reddy & his whole team are tremendous.
Very positive & informative interaction.
Never received a call back from Dr. Reddy after he reviewed the case. Kaiser indicated he contacted them, but we didn't receive any correspondence from Dr. Reddy & PA.
Entire team is excellent. Check in staff, Dr. Reddy, Dr. Evan Hall, Jaime Reis, NP, Laura Morris, RN.
EVERY question answered w/out feeling rushed.
Sometimes waiting too long. Dr. Reddy kind of quiet, but explained all that was happening.
Good.
Dr. Reddy, Dr. Evan Hall & Laura Morris, RN are phenomenal. They are warm, friendly & caring every single time. Top notch professionals.
Dr. Reddy and his staff are wonderful.
Dr. Reddy and his staff (Laura, Jaime) have always been wonderful and supportive.
Dr. Reddy is a doctor's doctor.
Excellent care team. Great results!
Dr. Reddy is great! Such an excellent care provider.
5. No meds. 6. No follow up.
Was especially impressed where the doctor thanked us for coming 6 hrs. (out of our comfort zone) that he appreciated our confidence in him.
They are very active in the health of the people & also very expert in the care of the patients.
Always recommending my family and friends to Stanford great place and all of you can be very proud of your people you have working for you.
Dr. Reddy is a wonderful doctor.
Incredible doctor and staff!
Dr. Reddy is wonderful!
Good.
Outstanding.
Excellent people.
Dr. Reddy & Laura Morris are AWESOME! #10. Already have.
The whole staff including Dr., nurses & medical staff are all excellent professionals but still very nice & easy to talk with.
We felt Dr. Reddy, and staff knowledgeable respectful, able to teach/explain/answer all our questions. Dr. Reddy and Dr. Swang had a well thought out treatment plan to offer us hope. We left feeling we had gone to the "very best" medical center/doctors, we could have chosen!
Seemed rushed.
Dr. Reddy and Phoung Pham are excellent care providers.
Love my health care staff.
Dr. Sumil Reddy is an incredible doctor. Best ever.
Previously, Dr. Reddy seemed rushed and somewhat dismissive. This time, he was much more attentive and detailed.
Excellent attention.
Dr. Reddy and his staff are excellent!
Great experience with Dr. Reddy, Dr. Mascar, and Jamie Faris.
This was a very good experience a consultation that was not stressful at all.
Thanks for excellent service!
I would highly recommend Dr. Reddy.
Great thank you.
Dr. Reddy is awesome & I feel so blessed to have. He & his staff there for me!
Great doctor.
Dr. Reddy is wonderful - a great care provider.
Extremely pleased.
Dr. Reddy and Laura Morris are beyond fantastic!
Dr. Reddy rocks!!
I have recommended this provider with several people.
I cannot EVEN THINK of a sour note I have only good. I love my time at Stanford!
Excellent.
I have the highest praise for Dr. Reddy. He is personable and friendly, yet very professional. He answers questions well. I have complete confidence in his expertise.
Dr. Reddy was knowledgeable and relayed information in an easily understandable way. He was thorough & presented me with a variety of options. I totally trust his judgment.
I have recommended this care provider several times.
All those extra checks mean I have the best care & the best dr. & nurses - Thank you -
Very thorough, clear & patient w/my questions & concerns.
Dr. Reddy is a great doctor - caring, compassionate, kind and extremely knowledgeable.
Learned a significant amount of information about the medications I am taking.
We are always greeted with a smile and a good word.
I love Dr. Reddy!
The entire team, NP, PA & MD are all the best I could hope for, and I am fortunate to have them.
Dr. Kipp Weis kept was excellent - saw me first. dr. Reddy was outstanding.
I feel he has not informed me well enough as to what's happening, his concerns on explanations. I feel like I'm flying blind!!
I have recommended this provider to several people.
Good.
I have recommended him.
Dr. Reddy has been like a primary care physician. Very good.
Dr. Reddy is outstanding! His care and concern and availability dealing with my stage 4 melanoma problems are a great help.
Dr. Reddy is trying to do everything he can to save my life. I'm so grateful to have him as my dr.
Dr. Reddy is a caring hands on doctor who spends time knowing all issues of my cancer and provides me with excellent personalized service.
Provider seemed perfunctory and no follow-up.
Dr. Reddy and the PA spent an incredible amount of time with me.
Dr. Reddy - excellent doctor.
1 hr. w/me.
Dr. Reddy and David Nguyen spent a TON of time answering all our questions about cancer treatment. Very patient and thorough.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
- Send referrals online
- View referral status
- Access medical records